交银国际研报指出，考虑到目标价暗含65.1%潜在升幅，以及短期催化剂包括商业化产品的逐季放量、泰它西普MG、SS、IgAN 等适应症的关键数据读出和申报，目标价下调至24港元。Remegen (09995) fell more than 3%, at the time of publication, it fell 3.03% to HKD 14.1, with a turnover of HKD 20.1038 million.
Zhitong Finance APP learned that Remegen (09995) fell more than 3%, at the time of publication, it fell 3.03% to HKD 14.1, with a turnover of HKD 20.1038 million.
On the news front, Remegen recently released its 2024 mid-term performance with a revenue of CNY 0.74 billion, up 76.5% YoY, and a net loss of CNY 0.78 billion attributable to shareholders, expanding 10.96% YoY. The basic loss per share was CNY 1.45. No interim dividend will be paid. As of the first half of 2024, Remegen had a remaining balance of CNY 0.673 billion, a decrease of nearly 40% YoY.
According to Bocom Intl's research report, considering the target price implies a potential upside of 65.1% and the short-term catalysts including the gradual release of commercialized products, key data reading and applications for indications such as tislelizumab MG, SS, IgAN, the target price was lowered to HKD 24.